P098 Long-Term Infliximab in Crohn's Disease

Mendoza, Isabel Vera; Calvo, M.; Revilla, Juan de la; Abreu, Luís

doi:10.1016/s1873-9954(08)70109-5

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were 41 publications on CD , including 29 on luminal CD [7,8, and 8 on fistulizing CD [7,17,21,22,[44][45][46][47]. Eight studies did not distinguish long-term efficacy results between luminal and fistulizing CD patients [9,[37][38][39][40][41][42][43]. In UC, thirteen trials have been published on long-term anti-TNF use [11,17,21,[48][49][50][51][52][53][54][55][56][57], 3 of which included patients with severe disease [55][56][57].…”

Section: Resultsmentioning

confidence: 99%

“…Seven studies [9,[37][38][39][40][41][42] reported mixed results on the long-term efficacy of infliximab in CD cohorts, including both luminal and fistulizing CD, and one study [43] reported adalimumab efficacy in similar cohorts. In 13 patients with luminal and/or fistulizing CD, infliximab led to a complete response in 54% of patients (7/13) after a median follow-up of 13 months [37].…”

Section: Infliximabmentioning

confidence: 99%

“…There was a decrease in the mean annual surgery and perianal surgery rates of 70% and 57% in the remission group and the infliximab maintenance group, respectively [39]. In a retrospective study, the long-term maintenance of scheduled infliximab therapy was assessed in 44 patients with luminal and/or fistulizing CD for 2.2 years [40]. All patients had concomitant immunosuppression.…”

Section: Infliximabmentioning

confidence: 99%

“…Complete response (closure of the fistula or steroid suppression), partial response, and loss of response were noted in 82%, 7%, and 11% of patients, respectively [40]. The response rate beyond one year was significantly higher in patients with less than 10 years of disease duration (94.1% versus 66.7% p=0.03) [40]. Poupardin et al retrospectively evaluated 137 patients with luminal and/or fistulizing CD who received at least one infliximab infusion.…”

Section: Infliximabmentioning

confidence: 99%

“…The percentage of IBD patients who experienced at least one side effect during infliximab treatment ranged from 0% [52,55] to 61.3% in the study by Van Assche et al [28] Acute infusion reactions were assessed in 23 studies [7,9,10,19,20,34,35,37,38,40,41,44,48,50,52,55,56,58,[67][68][69][70][71]; their incidence ranged between 0% [52,55] and 16% [40]. Delayed infusion reactions were evaluated in 21 studies [7,9,19,20,34,37,38,40,41,44,48,50,52,55,56,58,[67][68][69][70]…”

Section: Safety Of Long-term Tnf Antagonist Therapy In Ibdmentioning

confidence: 99%

See 4 more Smart Citations

Efficacy of TNF Antagonists Beyond One Year in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Review

Oussalah¹,

Danese²,

Peyrin–Biroulet

2010

CDT

View full text Add to dashboard Cite

The introduction in the mid-1990s of tumor necrosis factor (TNF) antagonists changed the treatment of inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC) refractory to conventional medications (corticosteroids, immunomodulators). This review summarizes current data on the long-term efficacy and safety of anti-TNF therapy in IBD beyond 1 year. We searched Medline, the Cochrane Library, Embase, and Ovid Medliner for relevant studies. Infliximab, adalimumab and certolizumab are effective in maintaining clinical remission in luminal Crohn's disease. Infliximab and adalimumab are also effective in maintaining long-term fistula closure in Crohn's disease. Only infliximab has been evaluated in UC in the long term, with similar data on its effectiveness than in CD. In addition to the maintenance of clinical remission, TNF antagonists have the ability to maintain long-term mucosal healing, resulting in a reduced risk of surgery. With 2010 on the horizon, we have no good reasons to stop anti-TNF therapy in IBD patients because of its efficacy in maintaining remission and a risk-benefit ratio that remains in its favor. It is now clear that patients in deep remission, comprising clinical, biological, and endoscopic remission, are at lower risk of relapse after withdrawal of anti-TNF therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Infliximabmentioning

confidence: 99%

Section: Infliximabmentioning

confidence: 99%

Section: Infliximabmentioning

confidence: 99%

Section: Safety Of Long-term Tnf Antagonist Therapy In Ibdmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy of TNF Antagonists Beyond One Year in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Review

Oussalah¹,

Danese²,

Peyrin–Biroulet

2010

CDT

View full text Add to dashboard Cite

show abstract

Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn’s disease

et al. 2017

View full text Add to dashboard Cite

show abstract

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

2009

View full text Add to dashboard Cite

A variable but relevant proportion of Crohn's disease patients on long-term infliximab treatment lose response. This may be interpreted in two different but compatible ways: a positive view, highlighting that infliximab therapy is relatively durable, with the majority of patients predicted to continue infliximab treatment at least during the first year; or a negative view, interpreting that a significant proportion of Crohn's disease patients-more than 10% per patient-year of infliximab treatment-on long term will lose response and will require an increase in dose and/or decrease in infusion interval.

show abstract

P098 Long-Term Infliximab in Crohn's Disease

Cited by 4 publications

References 0 publications

Efficacy of TNF Antagonists Beyond One Year in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Review

Efficacy of TNF Antagonists Beyond One Year in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Review

Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn’s disease

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

Contact Info

Product

Resources

About